FeesSafety
Pluang+

Prelude Therapeutics advances cancer drug trials, reports Q3 2026 loss of $12.5M with cash runway into Q2 2028

Company Fundamentals
16 Nov 2026, 14:01 WIB
GlobeNewsWire
View Source
Bullish
Prelude Therapeutics advances cancer drug trials, reports Q3 2026 loss of $12.5M with cash runway into Q2 2028

Prelude Therapeutics reported Q3 2026 financial results with a net loss of $12.5 million and $142.7 million in cash, funding operations into Q2 2028. The company is progressing clinical trials for PRT13722, a selective KAT6A degrader for HR+ breast cancer, and PRT12396, a mutant-selective JAK2V617F inhibitor for blood cancers. A collaboration with Lilly supports combination therapy trials, and preclinical data for a novel mCALR-targeted antibody conjugate will be presented at an upcoming hematology conference. Multiple clinical readouts are expected in the next 12 to 18 months, positioning Prelude for growth in 2027.

Eli Lilly, collaborating with Prelude Therapeutics on cancer therapy trials, trades at USD 1,453.50 on Pluang with a 1-day gain of 0.69%. The stock's market cap stands at $1.29 trillion, reflecting its significant presence in the health sector. These figures are as of Nov 16, 2026, 18:41 WIB.

More News (LLY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App